Drug of Abuse (DOA) Testing

Drug of Abuse (DOA) Testing Comprehensive Study by Type (Rapid Test Kits, Assay Kits & Reagents, Immunoassay Analyzers, Others), End-users (Hospitals, Laboratories, At-Home, Others), Test (Onsite Screening Test, Laboratory Drug Testing), Sample (Urine, Saliva, Hair, Others) Players and Region - Global Market Outlook to 2027

Drug of Abuse (DOA) Testing Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Drug of Abuse (DOA) Testing Market Overview:
Drug of abuse (DOA) testing is frequently carried out in the clinical environment, however numerous studies analysing such screening have been unable to show any clinical advantage, and the majority of clinical toxicologists advise only getting such testing when there is a clear indication. The tools utilised in the market for drug misuse testing include breath analyzers, chromatography tools, and immunoassay analyzers. When compared to other approaches, immunoassay analyzers had the biggest market share among this equipment because they provide a quick, affordable, and practical way to screen lots of samples in various matrices.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Drug of Abuse (DOA) Testing Market Dynamics:
AttributesDetails
Growth Drivers
  • Rise Use of Drug Testing
  • Increasing Consumption of Illegal Drugs
Restraints
  • Not Being Aware Of the Harmful Impact of Unauthorized Drugs
Road Blocks / Challenges
  • Drugs to Carry Out Many Illegal Activities and the Abusers Consumed a Lot of Resources of the Country
Gaps & Opportunities
  • New product launches and R& D


Competitive Landscape:
The leading players had to compete with other market participants due to the expansion of drug misuse testing services and the adoption of various industry trends. The major businesses have developed a strong product portfolio by utilising a variety of items. In order to capture sizable market shares, they released new substances and deployed drug abuse test market technologies. These businesses and government agencies have prepared a number of plans that could result in the market for drug misuse testing devices being adopted. This pharmaceutical business has been spending a significant portion of its earnings to find new medications for the treatment of various disorders.
Some of the key players profiled in the report are Abbott Laboratories (United States), Quest Diagnostics Incorporated (United States), Express Diagnostics (United Kingdom), Thermo Fisher Scientific Inc., (United States), Siemens AG (Germany), Pfizer (United States), Dragerwerk AG & Co. KGAA Germany, OraSure (United States), Hoffmann-La Roche AG Switzerland and Premier Biotech (United States). Additionally, following companies can also be profiled that are part of our coverage like Alfa Scientific Designs (United States), SureHire (Canada), Omega Laboratories (United States) and CannAmm (Canada). Analyst at AMA Research see United States Players to retain maximum share of Global Drug of Abuse (DOA) Testing market by 2027. Considering Market by , the sub-segment i.e. will boost the Drug of Abuse (DOA) Testing market.

Prevention, operation, treatment, law enforcement, and interdiction are the five drug control functional areas that the National Drug Control Budget in the United States requested USD 34.6 billion for in FY 2020. This includes financing of USD 1.9 billion for the Substance Abuse Prevention and Treatment Block Grant, which will support evidence-based prevention initiatives, to be administered by the Substance Abuse and Mental Health Services Administration (SAMHSA). For monitoring and assisting drug interdiction operations as well as other counterdrug activities in the nation and other nations, the Department of Defense requested USD 1.2 billion.

What Can be Explored with the Drug of Abuse (DOA) Testing Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Drug of Abuse (DOA) Testing Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Drug of Abuse (DOA) Testing
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Drug of Abuse (DOA) Testing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Drug of Abuse (DOA) Testing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Drug of Abuse Testing Providers, Government Regulations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Rapid Test Kits
  • Assay Kits & Reagents
  • Immunoassay Analyzers
  • Others
By End-users
  • Hospitals
  • Laboratories
  • At-Home
  • Others

By Test
  • Onsite Screening Test
  • Laboratory Drug Testing

By Sample
  • Urine
  • Saliva
  • Hair
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise Use of Drug Testing
      • 3.2.2. Increasing Consumption of Illegal Drugs
    • 3.3. Market Challenges
      • 3.3.1. Drugs to Carry Out Many Illegal Activities and the Abusers Consumed a Lot of Resources of the Country
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements and Product Portfolio Expansion
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drug of Abuse (DOA) Testing, by Type, End-users, Test, Sample and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Drug of Abuse (DOA) Testing (Value)
      • 5.2.1. Global Drug of Abuse (DOA) Testing by: Type (Value)
        • 5.2.1.1. Rapid Test Kits
        • 5.2.1.2. Assay Kits & Reagents
        • 5.2.1.3. Immunoassay Analyzers
        • 5.2.1.4. Others
      • 5.2.2. Global Drug of Abuse (DOA) Testing by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Laboratories
        • 5.2.2.3. At-Home
        • 5.2.2.4. Others
      • 5.2.3. Global Drug of Abuse (DOA) Testing by: Test (Value)
        • 5.2.3.1. Onsite Screening Test
        • 5.2.3.2. Laboratory Drug Testing
      • 5.2.4. Global Drug of Abuse (DOA) Testing by: Sample (Value)
        • 5.2.4.1. Urine
        • 5.2.4.2. Saliva
        • 5.2.4.3. Hair
        • 5.2.4.4. Others
      • 5.2.5. Global Drug of Abuse (DOA) Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Drug of Abuse (DOA) Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Quest Diagnostics Incorporated (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Express Diagnostics (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific Inc., (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Siemens AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dragerwerk AG & Co. KGAA Germany
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. OraSure (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hoffmann-La Roche AG Switzerland
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Premier Biotech (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drug of Abuse (DOA) Testing Sale, by Type, End-users, Test, Sample and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Drug of Abuse (DOA) Testing (Value)
      • 7.2.1. Global Drug of Abuse (DOA) Testing by: Type (Value)
        • 7.2.1.1. Rapid Test Kits
        • 7.2.1.2. Assay Kits & Reagents
        • 7.2.1.3. Immunoassay Analyzers
        • 7.2.1.4. Others
      • 7.2.2. Global Drug of Abuse (DOA) Testing by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Laboratories
        • 7.2.2.3. At-Home
        • 7.2.2.4. Others
      • 7.2.3. Global Drug of Abuse (DOA) Testing by: Test (Value)
        • 7.2.3.1. Onsite Screening Test
        • 7.2.3.2. Laboratory Drug Testing
      • 7.2.4. Global Drug of Abuse (DOA) Testing by: Sample (Value)
        • 7.2.4.1. Urine
        • 7.2.4.2. Saliva
        • 7.2.4.3. Hair
        • 7.2.4.4. Others
      • 7.2.5. Global Drug of Abuse (DOA) Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drug of Abuse (DOA) Testing: by Type(USD Million)
  • Table 2. Drug of Abuse (DOA) Testing Rapid Test Kits , by Region USD Million (2016-2021)
  • Table 3. Drug of Abuse (DOA) Testing Assay Kits & Reagents , by Region USD Million (2016-2021)
  • Table 4. Drug of Abuse (DOA) Testing Immunoassay Analyzers , by Region USD Million (2016-2021)
  • Table 5. Drug of Abuse (DOA) Testing Others , by Region USD Million (2016-2021)
  • Table 6. Drug of Abuse (DOA) Testing: by End-users(USD Million)
  • Table 7. Drug of Abuse (DOA) Testing Hospitals , by Region USD Million (2016-2021)
  • Table 8. Drug of Abuse (DOA) Testing Laboratories , by Region USD Million (2016-2021)
  • Table 9. Drug of Abuse (DOA) Testing At-Home , by Region USD Million (2016-2021)
  • Table 10. Drug of Abuse (DOA) Testing Others , by Region USD Million (2016-2021)
  • Table 11. Drug of Abuse (DOA) Testing: by Test(USD Million)
  • Table 12. Drug of Abuse (DOA) Testing Onsite Screening Test , by Region USD Million (2016-2021)
  • Table 13. Drug of Abuse (DOA) Testing Laboratory Drug Testing , by Region USD Million (2016-2021)
  • Table 14. Drug of Abuse (DOA) Testing: by Sample(USD Million)
  • Table 15. Drug of Abuse (DOA) Testing Urine , by Region USD Million (2016-2021)
  • Table 16. Drug of Abuse (DOA) Testing Saliva , by Region USD Million (2016-2021)
  • Table 17. Drug of Abuse (DOA) Testing Hair , by Region USD Million (2016-2021)
  • Table 18. Drug of Abuse (DOA) Testing Others , by Region USD Million (2016-2021)
  • Table 19. South America Drug of Abuse (DOA) Testing, by Country USD Million (2016-2021)
  • Table 20. South America Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 21. South America Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 22. South America Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 23. South America Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 24. Brazil Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 25. Brazil Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 26. Brazil Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 27. Brazil Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 28. Argentina Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 29. Argentina Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 30. Argentina Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 31. Argentina Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 32. Rest of South America Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 33. Rest of South America Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 34. Rest of South America Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 35. Rest of South America Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 36. Asia Pacific Drug of Abuse (DOA) Testing, by Country USD Million (2016-2021)
  • Table 37. Asia Pacific Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 38. Asia Pacific Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 39. Asia Pacific Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 40. Asia Pacific Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 41. China Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 42. China Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 43. China Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 44. China Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 45. Japan Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 46. Japan Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 47. Japan Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 48. Japan Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 49. India Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 50. India Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 51. India Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 52. India Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 53. South Korea Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 54. South Korea Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 55. South Korea Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 56. South Korea Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 57. Taiwan Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 58. Taiwan Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 59. Taiwan Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 60. Taiwan Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 61. Australia Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 62. Australia Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 63. Australia Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 64. Australia Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 66. Rest of Asia-Pacific Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 69. Europe Drug of Abuse (DOA) Testing, by Country USD Million (2016-2021)
  • Table 70. Europe Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 71. Europe Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 72. Europe Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 73. Europe Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 74. Germany Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 75. Germany Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 76. Germany Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 77. Germany Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 78. France Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 79. France Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 80. France Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 81. France Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 82. Italy Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 83. Italy Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 84. Italy Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 85. Italy Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 86. United Kingdom Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 87. United Kingdom Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 88. United Kingdom Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 89. United Kingdom Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 90. Netherlands Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 91. Netherlands Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 92. Netherlands Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 93. Netherlands Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 94. Rest of Europe Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 95. Rest of Europe Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 96. Rest of Europe Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 97. Rest of Europe Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 98. MEA Drug of Abuse (DOA) Testing, by Country USD Million (2016-2021)
  • Table 99. MEA Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 100. MEA Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 101. MEA Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 102. MEA Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 103. Middle East Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 104. Middle East Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 105. Middle East Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 106. Middle East Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 107. Africa Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 108. Africa Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 109. Africa Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 110. Africa Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 111. North America Drug of Abuse (DOA) Testing, by Country USD Million (2016-2021)
  • Table 112. North America Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 113. North America Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 114. North America Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 115. North America Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 116. United States Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 117. United States Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 118. United States Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 119. United States Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 120. Canada Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 121. Canada Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 122. Canada Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 123. Canada Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 124. Mexico Drug of Abuse (DOA) Testing, by Type USD Million (2016-2021)
  • Table 125. Mexico Drug of Abuse (DOA) Testing, by End-users USD Million (2016-2021)
  • Table 126. Mexico Drug of Abuse (DOA) Testing, by Test USD Million (2016-2021)
  • Table 127. Mexico Drug of Abuse (DOA) Testing, by Sample USD Million (2016-2021)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Drug of Abuse (DOA) Testing: by Type(USD Million)
  • Table 139. Drug of Abuse (DOA) Testing Rapid Test Kits , by Region USD Million (2022-2027)
  • Table 140. Drug of Abuse (DOA) Testing Assay Kits & Reagents , by Region USD Million (2022-2027)
  • Table 141. Drug of Abuse (DOA) Testing Immunoassay Analyzers , by Region USD Million (2022-2027)
  • Table 142. Drug of Abuse (DOA) Testing Others , by Region USD Million (2022-2027)
  • Table 143. Drug of Abuse (DOA) Testing: by End-users(USD Million)
  • Table 144. Drug of Abuse (DOA) Testing Hospitals , by Region USD Million (2022-2027)
  • Table 145. Drug of Abuse (DOA) Testing Laboratories , by Region USD Million (2022-2027)
  • Table 146. Drug of Abuse (DOA) Testing At-Home , by Region USD Million (2022-2027)
  • Table 147. Drug of Abuse (DOA) Testing Others , by Region USD Million (2022-2027)
  • Table 148. Drug of Abuse (DOA) Testing: by Test(USD Million)
  • Table 149. Drug of Abuse (DOA) Testing Onsite Screening Test , by Region USD Million (2022-2027)
  • Table 150. Drug of Abuse (DOA) Testing Laboratory Drug Testing , by Region USD Million (2022-2027)
  • Table 151. Drug of Abuse (DOA) Testing: by Sample(USD Million)
  • Table 152. Drug of Abuse (DOA) Testing Urine , by Region USD Million (2022-2027)
  • Table 153. Drug of Abuse (DOA) Testing Saliva , by Region USD Million (2022-2027)
  • Table 154. Drug of Abuse (DOA) Testing Hair , by Region USD Million (2022-2027)
  • Table 155. Drug of Abuse (DOA) Testing Others , by Region USD Million (2022-2027)
  • Table 156. South America Drug of Abuse (DOA) Testing, by Country USD Million (2022-2027)
  • Table 157. South America Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 158. South America Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 159. South America Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 160. South America Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 161. Brazil Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 162. Brazil Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 163. Brazil Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 164. Brazil Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 165. Argentina Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 166. Argentina Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 167. Argentina Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 168. Argentina Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 169. Rest of South America Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 170. Rest of South America Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 171. Rest of South America Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 172. Rest of South America Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 173. Asia Pacific Drug of Abuse (DOA) Testing, by Country USD Million (2022-2027)
  • Table 174. Asia Pacific Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 175. Asia Pacific Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 176. Asia Pacific Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 177. Asia Pacific Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 178. China Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 179. China Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 180. China Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 181. China Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 182. Japan Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 183. Japan Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 184. Japan Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 185. Japan Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 186. India Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 187. India Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 188. India Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 189. India Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 190. South Korea Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 191. South Korea Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 192. South Korea Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 193. South Korea Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 194. Taiwan Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 195. Taiwan Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 196. Taiwan Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 197. Taiwan Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 198. Australia Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 199. Australia Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 200. Australia Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 201. Australia Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 202. Rest of Asia-Pacific Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 203. Rest of Asia-Pacific Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 204. Rest of Asia-Pacific Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 205. Rest of Asia-Pacific Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 206. Europe Drug of Abuse (DOA) Testing, by Country USD Million (2022-2027)
  • Table 207. Europe Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 208. Europe Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 209. Europe Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 210. Europe Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 211. Germany Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 212. Germany Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 213. Germany Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 214. Germany Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 215. France Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 216. France Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 217. France Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 218. France Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 219. Italy Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 220. Italy Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 221. Italy Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 222. Italy Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 223. United Kingdom Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 224. United Kingdom Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 225. United Kingdom Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 226. United Kingdom Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 227. Netherlands Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 228. Netherlands Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 229. Netherlands Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 230. Netherlands Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 231. Rest of Europe Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 232. Rest of Europe Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 233. Rest of Europe Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 234. Rest of Europe Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 235. MEA Drug of Abuse (DOA) Testing, by Country USD Million (2022-2027)
  • Table 236. MEA Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 237. MEA Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 238. MEA Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 239. MEA Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 240. Middle East Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 241. Middle East Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 242. Middle East Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 243. Middle East Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 244. Africa Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 245. Africa Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 246. Africa Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 247. Africa Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 248. North America Drug of Abuse (DOA) Testing, by Country USD Million (2022-2027)
  • Table 249. North America Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 250. North America Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 251. North America Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 252. North America Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 253. United States Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 254. United States Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 255. United States Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 256. United States Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 257. Canada Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 258. Canada Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 259. Canada Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 260. Canada Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 261. Mexico Drug of Abuse (DOA) Testing, by Type USD Million (2022-2027)
  • Table 262. Mexico Drug of Abuse (DOA) Testing, by End-users USD Million (2022-2027)
  • Table 263. Mexico Drug of Abuse (DOA) Testing, by Test USD Million (2022-2027)
  • Table 264. Mexico Drug of Abuse (DOA) Testing, by Sample USD Million (2022-2027)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drug of Abuse (DOA) Testing: by Type USD Million (2016-2021)
  • Figure 5. Global Drug of Abuse (DOA) Testing: by End-users USD Million (2016-2021)
  • Figure 6. Global Drug of Abuse (DOA) Testing: by Test USD Million (2016-2021)
  • Figure 7. Global Drug of Abuse (DOA) Testing: by Sample USD Million (2016-2021)
  • Figure 8. South America Drug of Abuse (DOA) Testing Share (%), by Country
  • Figure 9. Asia Pacific Drug of Abuse (DOA) Testing Share (%), by Country
  • Figure 10. Europe Drug of Abuse (DOA) Testing Share (%), by Country
  • Figure 11. MEA Drug of Abuse (DOA) Testing Share (%), by Country
  • Figure 12. North America Drug of Abuse (DOA) Testing Share (%), by Country
  • Figure 13. Global Drug of Abuse (DOA) Testing share by Players 2021 (%)
  • Figure 14. Global Drug of Abuse (DOA) Testing share by Players (Top 3) 2021(%)
  • Figure 15. Global Drug of Abuse (DOA) Testing share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 19. Quest Diagnostics Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 20. Quest Diagnostics Incorporated (United States) Revenue: by Geography 2021
  • Figure 21. Express Diagnostics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. Express Diagnostics (United Kingdom) Revenue: by Geography 2021
  • Figure 23. Thermo Fisher Scientific Inc., (United States) Revenue, Net Income and Gross profit
  • Figure 24. Thermo Fisher Scientific Inc., (United States) Revenue: by Geography 2021
  • Figure 25. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Siemens AG (Germany) Revenue: by Geography 2021
  • Figure 27. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (United States) Revenue: by Geography 2021
  • Figure 29. Dragerwerk AG & Co. KGAA Germany Revenue, Net Income and Gross profit
  • Figure 30. Dragerwerk AG & Co. KGAA Germany Revenue: by Geography 2021
  • Figure 31. OraSure (United States) Revenue, Net Income and Gross profit
  • Figure 32. OraSure (United States) Revenue: by Geography 2021
  • Figure 33. Hoffmann-La Roche AG Switzerland Revenue, Net Income and Gross profit
  • Figure 34. Hoffmann-La Roche AG Switzerland Revenue: by Geography 2021
  • Figure 35. Premier Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 36. Premier Biotech (United States) Revenue: by Geography 2021
  • Figure 37. Global Drug of Abuse (DOA) Testing: by Type USD Million (2022-2027)
  • Figure 38. Global Drug of Abuse (DOA) Testing: by End-users USD Million (2022-2027)
  • Figure 39. Global Drug of Abuse (DOA) Testing: by Test USD Million (2022-2027)
  • Figure 40. Global Drug of Abuse (DOA) Testing: by Sample USD Million (2022-2027)
  • Figure 41. South America Drug of Abuse (DOA) Testing Share (%), by Country
  • Figure 42. Asia Pacific Drug of Abuse (DOA) Testing Share (%), by Country
  • Figure 43. Europe Drug of Abuse (DOA) Testing Share (%), by Country
  • Figure 44. MEA Drug of Abuse (DOA) Testing Share (%), by Country
  • Figure 45. North America Drug of Abuse (DOA) Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Quest Diagnostics Incorporated (United States)
  • Express Diagnostics (United Kingdom)
  • Thermo Fisher Scientific Inc., (United States)
  • Siemens AG (Germany)
  • Pfizer (United States)
  • Dragerwerk AG & Co. KGAA Germany
  • OraSure (United States)
  • Hoffmann-La Roche AG Switzerland
  • Premier Biotech (United States)
Additional players considered in the study are as follows:
Alfa Scientific Designs (United States) , SureHire (Canada) , Omega Laboratories (United States) , CannAmm (Canada)
Select User Access Type

Key Highlights of Report


Aug 2022 209 Pages 79 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Drug of Abuse (DOA) Testing Quantitative research analysis
Drug of Abuse (DOA) Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Drug of Abuse (DOA) Testing market are Abbott Laboratories (United States), Quest Diagnostics Incorporated (United States), Express Diagnostics (United Kingdom), Thermo Fisher Scientific Inc., (United States), Siemens AG (Germany), Pfizer (United States), Dragerwerk AG & Co. KGAA Germany, OraSure (United States), Hoffmann-La Roche AG Switzerland and Premier Biotech (United States), to name a few.
"Technological Advancements and Product Portfolio Expansion" is seen as one of major influencing trends for Drug of Abuse (DOA) Testing Market during projected period 2021-2027.
Rapid Test Kits segment in Global market to hold robust market share owing to "Rise Use of Drug Testing ".

Know More About Drug of Abuse (DOA) Testing Report?

Have a Query? Click Here

Other Related Reports

Cancer Tumor Profiling Comprehensive Study by Type (Breast Cancer, Lung Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Others (Melanoma, Colorectal, Bladder, Leukemia)), Application (Clinica...
$ 3750
Body Fat Reduction Comprehensive Study by Application (Hospitals, Clinics, Medical Spas), End use (Personal use, Professional use), Procedure (Surgical, Nonsurgical), Gender (Male, Female) Players an...
$ 3500
Child Day Care Services Comprehensive Study by Type (Full-Day Child Care Centers, Part-Day Child Care Programs (Includes Nursery And Preschools), School-Age Child Care Programs, Kindergarten – Offere...
$ 3750
Patient Recruitment and Retention Services Comprehensive Study by Type (Patient Recruitment, Patient Retention, Other Services), Application (Oncology, Infectious Diseases, Cardiovascular Diseases, C...
$ 3450
Gastrointestinal Disorder Therapeutics Comprehensive Study by Type (Branded, Generics), Application (Ulcerative Colitis, Crohn’s Disease, GERD, Others), Distribution Channel (Hospital Pharmacies, Ret...
$ 3800
Biologics Outsourcing Comprehensive Study by Type (Antibody, Recombinant, Protein, Vaccines, Others), Application (Vaccine & Therapeutics Development, Blood & Blood Related Products Testing, Cellular...
$ 3650